Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer

Fallon E. Chipidza, Mohammed Alshalalfa, Brandon A. Mahal, R. Jeffrey Karnes, Yang Liu, Elai Davicioni, Neil E. Martin, Kent W. Mouw, Felix Y. Feng, Paul L. Nguyen, Vinayak Muralidhar

Research output: Contribution to journalArticlepeer-review

Abstract

TP53 is the most frequently mutated gene in cancer. We developed a molecular signature detecting underlying TP53 alterations. This signature identified aggressive tumors, and after adjusting for known predictors of worse outcomes, the signature identified patients with prostate cancer likely to develop metastases. These findings may help doctors identify patients with prostate cancer with aggressive tumors and hence, choose the optimal treatment.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • Biologic signature
  • Genomic classifier
  • Risk stratification
  • TCGA prostate
  • TP53 gene

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer'. Together they form a unique fingerprint.

Cite this